# Zepbound vs. Wegovy: Which GLP-1 Drug Is Best for Weight Loss?
Both Zepbound and Wegovy belong to the same class of medications called GLP-1 receptor agonists, but they carry different FDA approvals and serve distinct patient populations.
Wegovy, made by Novo Nordisk, received FDA approval in 2021 specifically for chronic weight management in adults with obesity or overweight who have at least one weight-related health condition. The drug works by mimicking glucagon-like peptide-1, a hormone that regulates appetite and blood sugar. Clinical trials showed people using Wegovy lost approximately 15 percent of their body weight on average, with some participants losing significantly more.
Zepbound, also made by Novo Nordisk, carries the same active ingredient as Wegovy but received FDA approval in 2023 specifically for weight loss. The distinction matters legally and medically. Zepbound targets the same mechanism but serves patients seeking weight management benefits beyond treating obesity-related conditions.
Both medications require weekly injections and involve gradual dose escalation over 16 to 20 weeks. Common side effects include nausea, vomiting, diarrhea, and constipation, particularly during dose increases. Serious but rare complications involve pancreatitis and gallbladder issues.
The practical choice between them often comes down to insurance coverage and individual medical history. Insurance plans may cover Wegovy for weight loss associated with health conditions like diabetes or hypertension, while coverage for Zepbound purely for weight management varies by plan. Both require ongoing use, as weight typically returns when people stop the medication.
Patients considering either option should discuss their specific health situation with their doctor. These medications work best alongside lifestyle changes including diet and exercise. Neither drug suits pregnant people or